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Summary: The concentrations of aminoterminal propeptides of procollagen type III were determined by
radioimmunoassay in the cerebrospinal fluids of 64 patients with various neurological disorders, including 4
infant patients (< l year). In cerebrospinal fluids of adult patients with normal composition (protein, glucose,
cell count), adult patients with pathologic composition, and infant patients the peptide levels (mean value
± S.D.) were 4.07 ± 1.26|jg/l, 8.15 ± 6.78 g/l, and 56.9 ± 31.0 «/1, respectively. The concentrations
ranged from 1.96 to 265 g/l and were independent of the respective serum propeptide levels. No statistic
correlation with other parameters was found. Gel chromatography revealed a high degree of molecular weight
heterogeneity, a substantial portion of immunoreactive material was eluted even with the void volume of
Sephacryl S 300. Different slopes of radioimmunoinhibition curves indicate heterogenous antigenicity among
the propeptides from various patients. Interactioii of the propeptides with fibronectin and/or heparin is prob-
ably not responsible for the heterogeneity. The diagnostic potential of cerebrospinal fluid propeptide levels
for local connective tissue (collagen) turnover remains to be elucidated.
Aminoterminale Propeptide von Typ III Prokollagen im Liquor cerebrospinalis des Menschen
Zusammenfassung: Im Liquor cerebrospinalis von 64 Patienten mit verschiedenen neurologischen Erkran-
kungen einschließlich 4 Kleinkindern (< l Jahr) wurden die Konzentrationen der aminoterminalen Pro-
peptide von Prokollagen Typ III mit einem Radioimmunoassay bestimmt. In Liquores von erwachsenen Pa-
tienten mit normaler Zusammensetzung (Protein, Glucose, Zellzahl), erwachsenen Patienten mit patholo-
gischer Zusammensetzung und Kleinkindern wurden Peptidkonzentrationen (Mittelwert ± S.D.) von 4,07 ±
1,26 |ig/l, 8,15 ± 6,78 §/1 bzw. 56,9 ± 31,0 g/l gemessen. Die Konzentrationen erstreckten sich von 1,96
bis 265 g/l und waren unabhängig von der jeweiligen Propeptid-Konzentration im Serum. Eine statistische
Korrelation mit änderen Kenngrößen besteht nicht. Gelchromatographie weist einen hohen Grad an Hetero-
genitat bezüglich des Molekulargewichtes nach, ein beträchtlicher Anteil des immunreaktiven Materials wird
mit dem Ausschlußvolumen von Sephacryl S 300 eluiert. Unterschiede in den Steigungen der Radioimmuno-
Inhibitionskürven weisen auf heterogene Antigenität der Propeptide verschiedener Patienten hin. Interak-
tionen der Propeptide mit Fibronectin und/oder Heparin sind wahrscheinlich nicht verantwortlich für diese
Heterogenität. Die diagnostische Bedeutung der Propeptidkonzentrationen im Liquor cerebrospinalis für den
lokalen Bindegewebsstoffwechsel bedarf weiterer Klärung.
n ro uc collagen mRNA is translated initially into a prepro-
Collagen is a major secretory protein of a large collagen having NHa-terminal hydrophobic exten-
mimber of eukaryotic cells. Like other proteins sions ("signal sequences") (4) which are required for
(1—3) synthesized on membrane bound polysomes the unidirectional transfer of the nascent polypep-
and destined for export into the extracellular space, tide into the lumen of the endoplasmic reticulum (5).
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These sequences are removed intracellularly by en-
doproteolytic activities to yield procollagen. After
secretion the procollagen molecule is further modi-
fied by procollagen peptidases cleaving both from
the amino-and carboxy-terminal end propeptides (6,
7) which can be determined by competitive radioim-
munoassays in various human body fluids such s se-
rum, urine, amniotic and ascitic fluid (8-11). The
aminoterminal propeptide of type III procollagen in
serum has been suggested s a sensitive parameter
for diagnosis and follow up of fibroproliferative liver
disorders (12, 13). In human cerebrospinal fluid the
presence of the carboxyterminal propeptide of type I
procollagen was claimed (14) but details are missing.
In addition, there are no reports on the aminotermi-
nal propeptide of type III procollagen in cerebrospi-
nal fluid available. Because the cleavage product f
Collagen processing might be a candidate parameter
of local connective tissue (collagen) formation activi-
ty, we measured the peptide in cerebrospinal fluid of
adult and infanV patients with various neurological
disorders and determined the molecular weight com-
position and some of the antigenic properties of the
procollagen propeptides.
weight gel Filtration calibration kit (Pharmacia) indicated in figure
3. V0 was determined with thyroglobulin (Λ/Γ 669000), Vt with
NAD+ (Mt = 681). Cerebrospinal fluid (l ml, containing 4.6 ng
propeptide) diluted with 0.5 ml Tris-HCl buffer was applied and
the effluent fractionated into l ml portions in which the relative
peptide concentrations indicated by % Inhibition of the binding of
125I-labeled bovine propeptide to the anjibody were recorded.
The Kav = was determined and the molecular weights oft— V0
the main fractions (I-IV) were calculated by use of the calibra-
tion curve.
Interaction of procollagen peptides with fibronectin and heparin
To study some possible interactions of procollagen peptides with
fibronectin and heparin various dilutions of cerebrospinal fluids in
phosphate-buffered saline were incubated in a total volume of
1.2 ml for l h at 4 °C and 37 °C, with 10 μg human plasma fibro-
nectin (lot. F-2006, Sigma Chemical Comp., M nchen) and/or
50 μg heparin (from porcine intestinal mucosa, Sigma Chemical
Comp.); control safnpies were incubated in the absence of both
compounds. Thereafter the elution profiles of procollagen pep-
tides from a Sephacryl S 300 column ( I x 115cm), calibrated
with molecular weight Standard proteins s above, were reeorded.
In addition, radioimmuno-inhibition curves of the various procol-
lagen peptide incubations were tested. Details are described in the
legends to figures 5 and 6.
Statistical analysis
The significance of differences was tested with the Mann- Whitney
test (17).
Materials and Methods
Specimen collection
Cerebrospinal fluid was obtained by lumbar puncture from 60
adult patient with various neurological diseases including mainly
encephalitis, meningitis, multiple sclerosis, primary and secondary
tumours, insult, circulatory disturbances and polyneuropathy.
Four specimens from infant patients (> l year of age) were also
studied. In 5 cases, it was possible to sample cerebrospinal fluid on
more than one occasion (two to three times). The fluid was separ-
ated from cells by centrifugation (10 min, 2000 g) within 5 h after
lumbar puncture and stored until use at -20 °C. The sample was
regarded s pathologic if the concentration of total protein ex-
ceeded 0.45 g/l and/or the total cell count was above 4 μΓ1. Total
protein and glucose in cerebrospinal fluid were measured with a
biuret (15) and hexokinase method (16), respectively. Cells were
counted manually by routine procedures. In some cases the serum
of the patients was analysed simultaneously. One patient with his-
tological proven chronic active Non-A- Non-B-hepatitis served s
a control (fig. 3).
Determination of the aminoterminal propeptide of type III procol-
lagen
Various dilutions of cerebrospinal fluid in phosphate-buffered sa-
line (normally 1:2, 1:5, 1:10) were analysed for the propeptide
using a radioimmunoassay for aminoterminal procollagen III pep-
tide (Behring-Werke/Hoechst AG, Frankfurt) which has been de-
scribed in detail elsewhere (l 1). Trje intra-assay coefficient of va-
riation (CV) was 5.5% (x = 9.8 μg/l, n = 8), the inter-assay CV
was,8% (x 3.3 μg/l, n = 10).
Determination ofthe molecular weight composilion ofthe antigenic
material
A column (l x 120cm) of Sephadex G 100 (Pharmacia Fine
Chemicals, Uppsala) equilibrated with 0.1 mol/1 Tris-HCl, pH 7.4
(20 °C) was calibrated with Standard proteins of the low molecular
Results
Procollagen type III propeptide concentrations in
cerebrospinal fluid
Procollagen peptide was present in the cerebrospinal
fluid of each patient studied (fig*. l^The lowest con-
centration observed was 1.96 |ig/l, the highest 265
μg/l. Adult patients having both normal protein con^
centration and cell count were found to have a pep-
tide concentration (mean value ± S.D.) of 4.07 ±
1.26 μg/l, whereas infaiit patients (< l year of age)
exhibit a significantly higher (p = 0.001) level of
procollagen peptide in cerebrospinal fluid (56.9 ±
31.0 μg/l), despite a normal concentration of protein
and normal cell count (fig. 1). In adult patients with
pathologic composition (protein and/or cell count
above the reference r nge) of the cerebrospinal
fluid, the procollagen peptide concentrations ex-
ceeded in nearly 50% (7/15) the +2 SD limit of
adult patients with normal fluid composition (fig. 1).
The concentration (mean ± S.D.) was 8.15 ± 6.78
|jg/l, the two extreme concentrations obsefved (150
and 265 μg/l) were not included in the calculation of
the mean concentration. Thus, the level of propep-
tide in this group of patients is significantly higher
than that in adult patients with normal cerebrospinal
fluid (p = 0.0028) and significantly lower (p =
0.0356) than that in infant patients.
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Fig. 1. Frequcncy distribution of NHa-terminal procollagcn pep-
ti e type III concentrations in cerebrospinal fluids (CSF)
of adult patients having normal fluid composition (i.e. to-
tal protein, glucosc and cell count within the reference
r nge) (n = 45), infants (< l year) with normal cerebros-
pinal fluid (n = 4), and adult patients having at least one
of the parameters (protein, glucose, cell count) in the pa-
thologic r nge (n = 15). The mean concentrations ± S.D.
of each group are given. In the latter group the 2 patients
with peptide concentrations of 15C^g/l and more
(265 μ§/1) were excluded from the calculation of mean
value ± S.D. The dotted lines indicate the ± 2 S.D. limits
of peptide levels in adults with normal CSF composition.
A correlation of the peptide concentration with a
specific neurological disorder is not yet possible. The
patient having a peptide level of 265 μg/l suffered
from haemangioblastoma, while the patient with 150
μg/l pepticle was treated because of an aneurysm of
art. basilaris. Other patients with elevated procolla-
gen peptide concentrations suffered from tumours,
myelitis, or influenza encephalitis. Multiple sclerosis
(n = 6) was not associated with increased peptide
levels.
No statistical correlation was found between the
aminoterminal propeptide concentrations and the
concentration of total protein (r = 0.357), glucose,
or cell count.
The concentration of procollagen peptide in cere-
brospinal fluids can change quite rapidly (fig. 2). Pa-
tients studied repeatedly at intervals of 2 to 4 weeks
exhibited different peptide levels which are associat-
ed in some cases with similar changes of the total
protein concentration. However, there is by no
means a strict correlation between the quantitative
changes of both parameters (fig. 2).
In the patients studied, cerebrospinal fluid propep-
tide concentrations were found to be independent of
the respective peptide levels in serum (tab. 1). The
two patients with respectively low and highly elevat-
ed cerebrospinal fluid concentrations, showed sim-
ilar concentrations of the antigen in serum. Despite
identical peptide concentrations in blood, the con-
centration of the respective material in cerebrospinal
fluid might differ more than 14 fold (tab. 1).
Tab. 1. Serum: cerebrospinal fluid ratios of procollagen peptide
in six patients having normal and highly elevated concen-
trations of procollagen peptide in cerebrospinal fluid.
Procollagen peptide ^g/l)
Ccrebrospinal fluid Serum Cerebrospinal fluid
2.9
3.9
5.1
26.2
34.0
41.4
13.8
10.1
7.9
7.9
12.9
13.6
4.76
2.56
1.56
0.30
0.38
0.32
3.5
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Fig. 2. Follow up of the concentrations of procollagen peptide (·—·) and total protein (O-O) in cerebrospinal fluids of five patients.
The interval between the determinations was about 2-4 weeks, Clinical diagnosis:
A) art. basilaris aneurysm;
B) multiple sclerosis;
C) diagnosis uncertain, patient died;
D) prolapse of an intervertebral disk;
E) influenza encephalitis
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Heterogeneity of procollagen type IHpeptides in cere-
brospinal fluid .
Cerebrospinal fluid of a patient with polyneuropathy
(4.6 μg/l) was subjected to gel filtration on Sephadex
G 100 and the distribution of immunoreactive mate-
rial was recorded in the effluent Volume (fig. 3).
Four main fractions were obtained, and the bulk
fraction was eluted with the void volume of the co-
lumn. Qualitatively similar elution profiles of procol-
lagen peptides were obtained with the serum of a pa-
tient with chronic active hepatitis and with the pro-
collagen peptide Standard of bovine origin supplied
by the manufacturer (fig. 3).
The molecular weights corresponding to the peak
peptide fractions in figure 3 are listed in table 2.
They indicate the high molecular weight nature of
the bulk fraction (I) and similar molecular weight
distributions of propeptides in cerebrospinal fluid,
serum and Standard. Thus, the molecular weight of
antigenic material in cerebrospinal fluid comprises a
wide r nge which is far above that reported for the
aminoterminal propeptide (11).
Differences in the radioimmunoinhibition curves re-
veal further heterogeneity of the antigenic material
in cerebrospinal fluids. As illustrated in figure 4, the
Inhibition plots for cerebrospinal fluid and serum
showed different slopes, which are not dependent on
the concentration of the propeptide in the fluids.
Tab. 2. Molecular weights (daltons) of the peak fractions of pro-
collagen type III peptides in cerebrospinal fluid of a pa-
tient with polyneuropathy. They were calculated from the
Kav determined on Sephadex G 100 (fig. 3). The molecu-
lar weights of the peptides are cofnpared with those in the
serum of a patient with Non-A-Non-B-chronic active he-
patitis, and with the Standard procollagen III peptide sup-
plied by the manufacturer.
Peak fraction
I
II
III
IV
Cerebrospinal
fluid
> 100000
76000
45000
35000
Serum
> 100000
68000
41000
27000
Standard
procollagen
III peptide
> 100000
68000
56000
37000
Fibronectin binds efficiently to collagen and colla-
gen-derived fraginents (18—20), in particular of type
III origin. In addition, heparin was reported to en-
hance this binding (21). The possibility that hete-
rogeneity may be due to interaction of propeptides
with fibronectin and/or heparin was tested by gel
chromatography, and by radioimmunoinhibition
curves. Incubation at 37 °C or 4 °C of cerebrospinal
fluids with various amounts of fibronectin, normally
present in cerebrospinal fluid only in very low con-
centrations (22, 23), did not alter signific ntly the
elution profiles of propeptides from Sephacryl S 300
Ovolbumin Ribonucleose A
Thyroglobulin Albumin | Chyfn tfypsinogen |
(669) (67) (43) (25) (13.7)
NAD
(0.681)
22 30 38 46 54
E f f l u e n t volume (ml]
86 90
Fig. 3. Elution profiles from a Sephadex G 100 column of immunoreactive procoilagen peptides from cerebrospinal fluid of a patient
with polyneuropathy (O-O, concentration 4.6 μg/l), serum of a patient with chronic active hepatitis (Δ-Δ, concentration 44.2
μg/l), and of the procollagen peptide Standard (·-·> concentration 5.3 μg/l) supplied with the assay kit. the column was
equ ibrated with 0.1 mol/1 Tris-HCl, pH 7.4, calibrated with various molecular weight Standard proteins of which the k daltons
are given in parentheses. The four peak fractions (I-IV) are indicated; their molecular weights were esfimated from Kav (tab; 2).
J. Glin, Chem. Clin. Biochem. / Vol. 22, 1984 / No. 3
Gressner: Aminoterminal propeptides of type III procollagen in human CSF 241
90
70
50
30
•E 10
ε 90
70
50
30
10
0.03 0.05 0.1 0.2 0.5 1.0 2,0
(fig. 5). At the position where pure fibronectin elutes
from the column no immunreactive procollagen pep-
tide was detected.
The radioimmunoinhibition curves of cerebrospinal
fluid propeptide were not influenced by incubation
of the sample with fibronectin and/or heparin
. 6).
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Fig. 4. Radioimmunoinhibition curves of 3 cerebrospinal fluid
samples (a) and 5 serum samples (b) with various concen-
trations (μ§/1) indicated by the numbers. The samples
were diluted to give the final amounts (ng) of procollagen
peptide in the assay of which the potency to inhibit the
binding of bovine [125I]procolIagen III peptide to the anti-
body was tested (% Inhibition).
Fig. 6. Radioimmunoinhibition curves of a cerebrospinal fluid
sample in the presence of heparin (O—O), fibronectin
(D—D), heparin and fibronectin (*—*), and in the ab-
sence of both heparin and fibronectin (O—O).
1.0 ml of cerebrospinal fluid containing 10.5 ng procolla-
gen peptide was incubated for l h at 37 °C with 50 μg he-
parin and/or 10 μg fibronectin, controls were incubated
with phosphate-buffered saline alone. The Inhibition
curves were obtained s described in figure 4. Similar re-
sults were obtained by incubations at 4°C.
100
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Fibronectin
Albumin Chymotrypsinogen| O v o l b u m i n j Ribonuclease A
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III
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Fig. 5. Elution profiles from a Sephacryl S 300 column of cerebrospinal fluid immunreactive procollagen peptides in the presence
(O—O) and absence (·—·) of added fibronectin. The column was equilibrated with 0.1 mol/1 Tris-HCl, pH 7.4 and calibrated
with various molecular weight Standard proteins of which the k dal ton s are given in parentheses. Cerebrospinal fluid of 3 patients
was pooled. One portion of 0.9 ml (28.5 ng procollagen peptide) was subjected to gel chromatography directly, another portion
was incubated with 10 μg fibronectin for l h at 37 °C prior to gel chromatography. The elution profiles of immunoreactivc
procollagen peptides were recorded, the molecular weights of the peak fractions were calculated from Knv.
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Discussion
The results presented in this study demonstrate, in
human cerebrospinal fluid, the presence of antigenic
material that reacts with antibodies produced against
the aminoterminal propeptide of bovine type III
procollagen. Because of the high immunological
cross-reactivity between the respective human and
bovine propeptides (11) the immunreactive material
identified in cerebrospinal fluid most likely repre-
sents procollagen type III fragments. As previously
recognized (11) and described in more detail recent-
ly (24), the composition of the antigenic material in
serum is heterogenous with respect to its molecular
weight. The heterogeneity of the procollagen pep-
tides in cerebrospinal fluid described here resembles
that in the serum of a patient with chronic active he-
patitis, showing at least four peaks. The molecular
weight of the bulk fraction was found to be >
100000 which is in line with recent observations
(24) demonstratijig high molecular weight antigenic
material in serum, but different from the original re-
port (11) in identifying mainly a 45000 and 10000
dalton fraction of procollagen peptides in serum. A
substantial portion of procollagen peptides in cere-
brospinal fluid actually eluted with the void volume
of Sephacryl S 300.
The heterogeneity of the procollagen type III specif-
ic material in human body fluids is important in rela-
tion to the problem of its radioimmunologic determi-
nation, and for the understanding of the metabolic
fate of the circulating form of procollagen type III
fragments (24). Since the molecular weight of the
aminoterminal propeptide was reported to be 45 000
dalton (11, 13), the high molecular weight fraction
must represent either an aggregated form of the pro-
peptide (11) or a more complete fragment of the
procollagen molecule containing the aminoterminal
determinants. The former assumption seems to be
unlikely. It is therefore assumed that at least the high
molecular weight fraction does not derive from
cleavage of procollagen by the action of procollagen
peptidase during procollagen processing, but rather
from limited degradation of either newly synthesized
procollagen type III or of a procollagen species de-
posited in the matrix (24).
In the collagen molecule several binding sites for fi-
bronectin have been identified (18). Fibronectin, a
high molecular weight glycoprotein also termed cold
insoluble globulin (21), binds with high affinity to
collagens, preferentially to type III collagen, and this
binding is enhanced by heparin (18-21). Since fi-
bronectin is present in high concentrations in blood
the heterogeneity of propeptides in sefum could be
due to various degrees of molecular interactions. In
cerebrospinal fluid fibronectin is either absent or
present in low concentrations (22, 23) which offers
the possibility of testing the binding of added glyco-
protein to the propeptide under almost physiologic
ionic conditions. The results reported above do not
indicate such an interaction or the presence of free
binding sites on procollagen peptides. The data,
however, do not rule out the possibility that all avail·
able binding sites are occupied even by the low
amounts of fibronectin present in cerebrospinal
fluid. Neither the cells responsible for synthesis nor
the catabolic sites of the soluble procollagen pep^
tides in the cerebrospinal fluid compartment are
known. Thüs, the mechanisms controlling the level
of procollagen peptide in the fluid and affecting its
concentration under certain pathologic conditions
are presently not understood. The high concentra-
tion of the peptide in cerebrospinal fluids of all in-
fants studied might reflect accelerated collagen syn-
thetic activity and/or turnover during develppment
äs observed in serum (25). From the data presented
it seems highly unlikely that serum procollagen pep-
tides contribute to the level of the respective pep-
tides in cerebrospinal fluid. The maximüni concen-
tration observed (265 g/l) greatly exceeds that
measured so far in serum (13). This suggests that the
determination of cerebrospinal fluid procollagen
type III peptides might provide a potentially useful
parameter of local connective tissue formation and/
or turnover. With respect to the clinical significance
of the peptide in cerebrospinal fluid it is of interest
that the highest concentrations were observed in pa-
tients with art. basilaris aneurysm and haemangio-
blastoma, respectively. Both diseases might be asso-
ciated with altered collagen metabolism. Further stu-
dies are required for a clinical evaluation of the pro-
collagen type peptides in cerebrospinal fluid.
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